Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25357185 | 1.00 | TGM2 (0.51) | TGM2KMT2AMDM2MGLLTLR2 | |
| SCHEMBL25357858 | 1.00 | TGM2 (0.51) | TGM2KMT2AMDM2MGLLTLR2 | |
| SCHEMBL25358036 | 0.99 | KMT2A (0.51) | TGM2KMT2AMDM2MGLLTLR2 | |
| SCHEMBL25358031 | 0.99 | KMT2A (0.51) | TGM2KMT2AMDM2MGLLTLR2 | |
| SCHEMBL12684664 | 0.89 | TGM2 (0.64) | TGM2KMT2A | |
| SCHEMBL29989659 | 0.89 | TGM2 (0.46) | TGM2KMT2AMDM2MGLLTLR2 | |
| SCHEMBL26012135 | 0.89 | TGM2 (0.46) | TGM2KMT2AMDM2MGLLTLR2 | |
| SCHEMBL28915280 | 0.87 | TGM2 (0.51) | TGM2KMT2AMDM2TLR2MDM4 | |
| SCHEMBL28915281 | 0.87 | TGM2 (0.51) | TGM2KMT2AMDM2TLR2MDM4 | |
| SCHEMBL29989685 | 0.87 | TLR2 (0.46) | KMT2AMDM2MGLLTLR2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | TGM2 230/4885KMT2A 2979/4885MDM2 631/4885 |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | TGM2 187/4885KMT2A 3083/4885MDM2 423/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | TGM2 733/4885KMT2A 3415/4885MDM2 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.